Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer...

Area of Science:

• Oncology
• Pharmacology
• Drug Repurposing

Background:

• Metastatic endometrial cancer remains a significant cause of mortality despite current treatments.
• The drug repurposing movement identifies existing medications for novel anti-cancer applications.
• Targeting cancer growth drivers with repurposed drugs is a key strategy in oncology.

Purpose of the Study:

• To identify existing drugs with evidence of inhibiting endometrial cancer growth.
• To propose a novel combination regimen (EC5) for metastatic endometrial cancer.
• To evaluate the potential of repurposed drugs in managing advanced endometrial cancer.

Main Methods:

• Literature review of preclinical and clinical data for drug repurposing in endometrial cancer.
• In vitro screening of numerous drugs for endometrial cancer cell growth inhibition.
• Identification of five drugs meeting evidence criteria for the EC5 regimen.

Main Results:

• Five commonly used drugs demonstrate inhibitory effects on endometrial cancer growth.
• The EC5 regimen comprises alendronate, celecoxib, itraconazole, ramelteon, and simvastatin.
• These repurposed drugs are generally well-tolerated with minimal side effects.

Conclusions:

• The EC5 regimen presents a promising, evidence-based approach for treating metastatic endometrial cancer.
• Drug repurposing offers a viable strategy to develop new therapies for difficult-to-treat cancers.
• Further clinical investigation of the EC5 regimen is warranted for endometrial cancer patients.